Keyphrases
Agonist Treatment
10%
AKT2
30%
Arterial Blood
10%
Calpain
10%
CAMP Response Element-binding Protein
10%
Confidence Interval
10%
Controlled Crosses
10%
Disease-related
10%
EEF2
10%
Forkhead Box O1 (FOXO1)
20%
Fractional Synthesis Rate
20%
Intracellular Signaling
30%
Lean Mass
10%
MRNA Level
10%
Muscle Biopsy
20%
Muscle Protein Breakdown
10%
Muscle Protein Turnover
10%
Myofibrillar
20%
Myostatin
20%
Oral Treatment
10%
Phenylalanine
20%
Phosphorylation
20%
PKA Pathway
10%
Placebo
40%
Protein Production
100%
Protein Synthesis
10%
Quadriceps
10%
Randomized Placebo-controlled Trial
10%
Resistance Exercise
100%
Salbutamol
100%
Signaling Activation
10%
Skeletal muscle
100%
Skeletal muscle Protein Synthesis
10%
Smad3
10%
Treatment Duration
10%
Vastus Lateralis muscle
10%
Venous Blood
10%
Young Men
100%
β2-adrenoceptor
30%
β2-agonists
20%
Medicine and Dentistry
Arterial Blood
10%
Beta 2 Adrenergic Receptor
100%
Beta2 Agonist
20%
Cyclic AMP Dependent Protein Kinase
10%
Diseases
10%
DNA Responsive Element
10%
Infusion
10%
Intracellular Signaling
30%
Messenger RNA
70%
Muscle Atrophy
10%
Muscle Biopsy
20%
Muscle Protein
20%
Myostatin
20%
Phenylalanine
20%
Placebo
50%
Protein Binding
10%
Protein Degradation
100%
Protein Degradation
10%
Protein Synthesis
20%
Resistance Training
100%
Salbutamol
100%
Skeletal Muscle
100%
Sympathomimetic Drug
100%
Vastus Lateralis Muscle
10%
Venous Blood
10%
Pharmacology, Toxicology and Pharmaceutical Science
Adrenergic Receptor Stimulating Agent
100%
Albendazole
10%
Beta 2 Adrenergic Receptor
100%
Beta2 Agonist
20%
Binding Protein
10%
Calpain 1
10%
Cyclic AMP Dependent Protein Kinase
10%
Diseases
10%
Messenger RNA
70%
Muscle Atrophy
10%
Muscle Protein
20%
Myostatin
20%
Phenylalanine
20%
Placebo
50%
Salbutamol
100%